| Description | Manitimus (FK778) is an inhibitor of dehydroorotate dehydrogenase and an immunosuppressant with immunosuppressive and antiproliferative activity, prevents vascular remodeling after mechanical endothelial injury, and can be used to study immune dysfunction. |
| In vivo | 与对照组大鼠相比，Manitimus（15 mg/kg，口服）可显著减少新生内膜面积和狭窄百分比，并减少 CMV 感染导致静脉移植物内膜和内侧横截面积及内侧壁厚度显著增加的影响[2]。 在经 Manitimus 处理的大鼠中，存在与剂量相关的差异效应：第 4 组（Manitimus 5 mg/kg）的平均存活期为 15.7 天，第 5 组（Manitimus 10 mg/kg）为 19.1 天，第 6 组（Manitimus 20 mg/kg）为 25.4 天[1]。 |
| Synonyms | FK778 |
| molecular weight | 308.26 |
| Molecular formula | C15H11F3N2O2 |
| CAS | 202057-76-9 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Birnbaum F, et al. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model. Eye (Lond). 2007 Dec;21(12):1516-23. Epub 2007 Mar 30. 2. Kloppenburg G, et al. FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model. Intervirology. 2009;52(4):189-95. |